FibroGen, Inc. (FGEN)
NASDAQ: FGEN · IEX Real-Time Price · USD
0.743
-0.027 (-3.52%)
At close: Jul 2, 2024, 4:00 PM
0.780
+0.036 (4.91%)
After-hours: Jul 2, 2024, 5:32 PM EDT
FibroGen Revenue
FibroGen had revenue of $167.49M in the twelve months ending March 31, 2024, with 44.30% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $55.90M with 54.59% year-over-year growth. In the year 2023, FibroGen had annual revenue of $147.75M with 4.99% growth.
Revenue (ttm)
$167.49M
Revenue Growth
+44.30%
P/S Ratio
0.44
Revenue / Employee
$344,636
Employees
486
Market Cap
73.91M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 147.75M | 7.02M | 4.99% |
Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
Dec 31, 2018 | 212.96M | 81.96M | 62.57% |
Dec 31, 2017 | 131.00M | -52.19M | -28.49% |
Dec 31, 2016 | 183.19M | 2.36M | 1.31% |
Dec 31, 2015 | 180.83M | 43.23M | 31.41% |
Dec 31, 2014 | 137.60M | 35.43M | 34.68% |
Dec 31, 2013 | 102.17M | 36.24M | 54.96% |
Dec 31, 2012 | 65.93M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionFGEN News
- 4 weeks ago - FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials - GlobeNewsWire
- 4 weeks ago - FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors - GlobeNewsWire
- 5 weeks ago - FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 2 months ago - FibroGen to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - FibroGen Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - FibroGen to Report First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 3 months ago - FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire